HAVCR2 and cancer: In addition, co-expression of TIM3 and PD1 makes it another attractive target for targeted cancer immunotherapy, and co-blockade of TIM3 and programmed cell death1 (PD1) can lead to a reduction in tumor volume in preclinical models, warranting further study in the clinic (36).